Právní předpis byl sestaven k datu 20.12.2013.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
SDĚLENÍ
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx zahraničních věcí x. 58/2007 Xx. x. x. a x. 46/2008 Xx. x. x. x xxxxxxxxx sdělení Ministerstva xxxxxxxxxxxx xxxx č. 97/2012 Xx. x. x. x Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx
Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx xxx 12. listopadu 2012 xxxx xxxxxxxxx ředitelkou XXXXXX xxxxxxxx schválení xxxxxx xxxxx Xxxxxxx X - Seznamu xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx1).
X novým xxxxxx Xxxxxxx X xxxxxxxx souhlas Parlament Xxxxx republiky.
Nové xxxxx Xxxxxxx I xxxxxxxxx v xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx dne 1. ledna 2013 x xxxxx xxxx xxxxxxxxx v xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Dnem xxxxxx xxxxxx znění Xxxxxxx X v xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxx xx 1. xxxxx 2012 x vyhlášené xxx č. 97/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx I x xxxx překlad xx xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx přijatá xxx 19. xxxxx 2005 x Xxxxxx xxxx vyhlášena xxx č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.
XXXXXXX X
XXXXXX ZAKÁZANÝCH LÁTEK X XXXXX DOPINGU XXX ROK 2013
XXXXXXX XXXXXXXXXXXXX KODEX
Xxxxxx xx 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" kromě látek xx xxxxxx X1, X2, X4.4, X4.5 x X6(x) a Xxxxxxxxxx xxxxx X1, X2 x X3.
| &xxxx;
XXXXX X XXXXXX XXXXXXXX XXXXX
(XXX SOUTĚŽI X XXXX XXXXXX)
|
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx látka, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. léčiva x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx výzkumu xxxx xx ukončené xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), je xxxxxxxx stále.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):
(a) Xxxxxxxx* AAS, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); desoxymethyltestosteron (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; metribolon (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; norklostebol; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; prostanozol (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); quinbolon; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), androstendion (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx a xxxxxx xxxxxxxxxx a isomery, xxx ne x xxxxxxxx xxxxx xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
|
| &xxxx;
5α-xxxxxxxxx-3α,17β-xxxx
|
&xxxx; |
| &xxxx;
5α-xxxxxxxxx-3β,17α-xxxx
|
&xxxx;
xxx-xxxxxxxxxxxxxxxxxx
|
| &xxxx;
5α-xxxxxxxxx-3β,17β-xxxx
|
&xxxx;
xxxxxxxxxxxxxx
|
| &xxxx;
xxxxxxx-4-xx-3α,17α-xxxx
|
&xxxx;
3α-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-4-xx-3α,17β-xxxx
|
&xxxx;
3β-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
7α-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17α-xxxx
|
&xxxx;
7β-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17β-xxxX
|
&xxxx;
7-xxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
19-xxxxxxxxxxxxxx
|
| &xxxx;
4-xxxxxxxxxxxxx (androst-4-en-3β,17β-diol)
|
19-noretiocholanolon
|
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx modulátory androgenových xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, ale xx s xxxxxxxx xxxxx xx xx.
| &xxxx;
Xxx xxxxx skupiny xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x xxxxx, kterou xxxx xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " se xxxxxxxx k xxxxx, xxxxxx xxxx xxxx xxxxxxxxxx xxxxxxxxx.
|
X2. PEPTIDOVÉ HORMONY, XXXXXXX FAKTORY X XXXXXXXX XXXXX
Následující xxxxx a jejich xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (CG) a Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Xxxxxxxxxxxxxx;
4. Růstový xxxxxx (GH), xxxxxxxxxxxxx xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx xxxxxxx faktor (XXX), xxxxxxxx podobný xxxxxxx faktor-1 (XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx růstový faktor (XXXX), stejně xxxx xxxxxxxxx xxxx růstové xxxxxxx ovlivňující syntézu xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx zásobení, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových vláken;
x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.
X3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 agonisté xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x l-), xxxx xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 mikrogramů xx 24 hodin), xxxxxxxxxxx (maximálně 36 xxxxxxxxxx xx 24 xxxxx) x salmeterolu xxxxx xxxx xxxxxx x xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx režimem výrobce.
Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx a přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx laboratorní xxxxx, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx abnormální xxxxxxxx xxx xxxxxxxx xxxxxxxx terapeutické inhalační xxxxx xxxxx než xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX A XXXXXXXXXXX MODULÁTORY
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx s xxxxxxxx pouze xx xx.
2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:
Raloxifen, xxxxxxxxx, xxxxxxxxx, xxx xx x omezením xxxxx xx xx.
3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx s xxxxxxxx xxxxx xx ně.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx ně.
5. Metabolické xxxxxxxxxx:
x) Xxxxxxxx;
x) Xxxxxxxx delta xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx aktivované XXX x xxxxxxxxxxx x XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx kinase (XXXX) xxxx agonists/ (xxxx. XXXXX)
S5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x mannitolu), xxxxxxxxxx x xxxxx xxxxx s xxxxxxxxx xxxxxxxxxxxx účinky. Lokální xxxxxx xxxxxxxxxxxx xxx xxxxx anestézi není xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, spironolakton, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx a xxxxxxxxx xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Xxx xxxxxxx (Xxx Xxxxxxx, případně Xxxx Soutěž) jakéhokoliv xxxxxxxx xxxxx se xxxxxxxxxx xxxxxxxx xxxxxxx (xx. formoterol, salbutamol, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx spojení x xxxxxxxxxx nebo xxxxx xxxxxxxxx látkou je xxxxxxxxxx udělení specifické Xxxxxxxxxxxx xxxxxxx na xxxx látku navíc x té, která xxx xxxx udělena xx diuretikum xxxx xxxxx xxxxxxxxx látku.
ZAKÁZANÉ XXXXXX
M1. MANIPULACE X XXXX X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx xxxx nebo xxxxxxxxx krvinek a xxx podobných produktů xxxxxxxxxxx původu do xxxxxxxxx systému.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx dodávky xxxxxxx, zahrnující xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx založené xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx pouze xx xx. Suplementace xxxxxxxx zakázána xxxx.
3. Jakákoliv xxxxx xxxxxxxxxxxxxxx manipulace s xxxx xxxx x xxxxxxxx komponentami xxxxxxxxxxx xxxx chemickými xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Zakázané xx následující:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Vzorků xxxxxxxxxx při Xxxxxxxxx xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx záměnu x/xxxx xxxxxx (xxxx. xxxxxxxxxx) moči, ale xx x xxxxxxxx xxxxx xx xx.
2. Nitrožilní xxxxxx x/xxxx xxxxxxx xxxx xxx 50 ml xx 6 xxxxx xxxx zakázány xxxxx xxxxxx legitimně xxxxxxxxx x průběhu nemocničních xxxxxxx xxxx klinických xxxxxxxxxxxxx metod.
X3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx zakázáno xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx buněk;
|
XXXXX X METODY XXXXXXXX XXX SOUTĚŽI
|
Xxxxx xxxxxxxxx S0 xx X5 a X1 xx M3 xxxxxxxxx výše xxxx Xxx Soutěži xxxxxxxx x xxxxxxxxxxx xxxxxxx:
XXXXXXXX LÁTKY
X6. XXXXXXXXXXX
Všechna xxxxxxxxxxx xxxxxx všech xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-) xxxx xxxxxxxx, x výjimkou xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx místního xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx xxx 2013*.
Xxxxxxxxxxx zahrnují:
(a) Xxxxxxxxxxxx xxxxxxxxxxx:
Adrafinil, xxxxxxxxxx, amfetaminil, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, fenproporex, xxxxxxxxx, 4-xxxxxxxxxxxxxx (karfedon), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, kropropamid, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), methylendioxyamfetamin, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, modafinil, xxxxxxxxxxxxxx, p-methylamfetamin, prenylamin, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, etilefrin, xxxxxxxxxxx, fenkamfamin, fenprometamin, xxxxxxxxxx, isomethepten, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, pseudoefedrin*****selegilin, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx biologickými xxxxxx.
* Xxxxxxxxxxx xxxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, fenylefrin, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) nejsou xxxxxxxxxx xx Zakázané xxxxx.
** Lokální xxxxxx xxxxxxxxxx (např. nosní, xxxx xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky xxxx xxxxxxxx.
*** Xxxxx je xxxxxxxx xxxxx xxx koncentraci xxxxx xxx 5 xxxxxxxxxx v 1 xx xxxx.
**** Xxxxxxx a xxxxxxxxxxxxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx xxxx.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx jeho xxxxxxxxxxx v xxxx xx xxxxx než 150 xxxxxxxxxx xx xxxxxxxx
X7. NARKOTIKA
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, dextromoramid, diamorfin(heroin), xxxxxxxx a xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, petidin.
X8. XXXXXXXXXXX
Přírodní (xxxx. xxxxx, konopí x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (např. "Xxxxx" /XXX018, XXX073/ x XX-210) xxxx zakázané.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, nitrožilní xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
| &xxxx;
XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX
|
P1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Při Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Detekce se xxxx xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (FITA)
∙ Motocyklový xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
P2. XXXX-XXXXXXXXX
Pokud xxxx xxxxx určeno, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx Soutěži v xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxxxx (všechny xxxxxxxxxx) (XXXX)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx xxxxxx x xxxxxxxxxxx lyžování-skoky a X-xxxxx,x xxxxxxxxx X-xxxxx x "big xxx"
∙ Xxxxxxx (ISSF, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxx (XXX)
Beta-blokátory xxxxxxxx následující xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, levobunolol, xxxxxxxxxxxx, xxxxxxxxxx, nadolol, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x omezením xxxxx xx xx.
Xxxxxxxxx
Xxxxxx předpis x. 98/2013 Sb. x. x. xxxxx účinnosti xxxx 20.12.2013.
Xxxxxx xxxxxxx x. 98/2013 Xx. m. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. s xxxxxxxxx xx 20.9.2014.
Znění xxxxxxxxxxxx xxxxxxxx xxxxx jiných xxxxxxxx xxxxxxxx v xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx jich xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.